VTT and Dyadic International to Present Data on C1 Protein Platform at AAPS PharmSci 360 and PEGS Europe

Data Demonstrate C1 Can Be Developed Into a New-Generation Therapeutic Protein Production System

ESPOO, FINLAND and JUPITER, FL / ACCESSWIRE / November 5, 2018 / VTT Technical Research Centre of Finland Ltd (''VTT'') and Dyadic International, Inc. (OTCQX: DYAI)(''Dyadic'') will present data on the companies' ongoing R&D collaboration involving Dyadic's C1 Myceliophthora thermophila fungal strain at: AAPS PharmSci 360 in Washington, DC on November 7 and the PEGS Europe Protein & Antibody Engineering Summit in Lisbon, Portugal on November 14.

A poster titled ''Development of the Filamentous Fungus Myceliophthora thermophila C1 into a Next-Generation Therapeutic Protein Production System'' (Poster #W0930-06-047), coauthored by researchers at VTT and Dyadic, will be presented at AAPS PharmSci 360 in Washington, DC on Wednesday, November 7 from 9:30-10:30 AM ET. Among other findings, data show monoclonal antibodies (mAbs) have been produced in C1 with levels reaching 10.9 g/l and rates up to 2.4 g/l/day. Additionally, the researchers found that difficult to express proteins (viral antigens, virus-like particles, sensitive Fc fusion proteins and bispecific antibodies) have been produced in C1 at superior levels as compared with other production systems. Finally, the first steps of glycoengineering have been successful. To view this poster, please visit:

https://www.dyadic.com/wp-content/uploads/2018/01/AAPS-PharmSci-360-and-PEGS-Europe.pdf

An oral presentation titled ''Development of Myceliophthora thermophila into a Highly Productive Biologics Production Host'' will be given by Marika Vitikainen, Ph.D., Senior Scientist, Industrial Biotechnology and Food Solutions at VTT, at the PEGS Europe Protein & Antibody Engineering Summit in Lisbon, Portugal on Wednesday, November 14 at 3:05 PM WET. An overview of the presentation is available here: http://www.pegsummiteurope.com/optimising-protein-expression/#2

''In the C1 development program, VTT has collaborated with Dyadic to obtain a range of novel scientific findings regarding the specific physical properties of this filamentous fungal strain as well as its potential as a pharmaceutical platform,'' said Dr. Markku Saloheimu, Senior Principal Scientist at VTT. ''We believe this collaboration with Dyadic has shown that the C1 system has strong prospects for becoming a robust platform for therapeutic protein production.''

''Current production processes for therapeutic proteins using the Chinese hamster ovary (CHO) cell system are time-consuming and expensive,'' said Ronen Tchelet, Ph.D., VP Research and Business Development at Dyadic. ''Our most recent data reflects that high monoclonal (mAbs) and other antibodies production rates are achievable using Dyadic's C1 gene expression platform. This data indicates that C1can serve as a potential gene expression platform to produce various types of therapeutic proteins at higher levels than the commonly used systems. We look forward to sharing our progress with the pharmaceutical and biotechnology industries at these conferences.''

AAPS PharmSci 360, sponsored by the American Association of Pharmaceutical Scientists, features thousands of scientific posters featuring the latest, most innovative research in the field along with 7,000 attendees from around the globe including the best minds in the business. PEGS Europe is the largest European event covering all aspects of protein and antibody engineering.

About VTT Technical Research Centre of Finland Ltd

VTT Technical Research Centre of Finland Ltd is one of the leading research and technology organisations in Europe. VTT has a national mandate in Finland. We use our research and knowledge to provide expert services for our domestic and international customers and partners. We serve both private and public sectors. We have 75 years' experience supporting our clients growth with top-level research and science-based results. For more information, please visit https://www.vttresearch.com/.

About Dyadic International

Dyadic International, Inc. is a global biotechnology company which is developing what it believes will be a potentially significant biopharmaceutical gene expression platform based on the fungus Myceliophthora thermophila, named C1. The C1 microorganism, which enables the development and large scale manufacture of low cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. Dyadic is using the C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines (such as virus like particles (VLPs) and antigens), monoclonal antibodies, Fab antibody fragments, Fc-Fusion proteins, biosimilars and/or biobetters, and other therapeutic proteins. Dyadic pursues research and development collaborations, licensing arrangements and other commercial opportunities with its partners and collaborators to leverage the value and benefits of these technologies in development and manufacture of biopharmaceuticals. In particular, as the aging population grows in developed and undeveloped countries, Dyadic believes the C1 technology may help bring biologic drugs to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers and, hopefully, improve access and cost to patients and the healthcare system, but most importantly save lives.

Please visit Dyadic's website at http://www.dyadic.com for additional information, including details regarding Dyadic's plans for its biopharmaceutical business.

Dyadic trades on the OTCQX tier of the OTC marketplace. Investors can find real-time quotes, market information and financial reports for Dyadic in the Company's annual and quarterly reports which are filed with the OTC markets. Please visit the OTC markets website at www.otcmarkets.com/stock/DYAI/quote.

Safe Harbor Regarding Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as ''anticipate,'' ''believe,'' ''could,'' ''estimate,'' ''expect,'' ''goal,'' ''intend,'' ''look forward to,'' ''may,'' ''plan,'' ''potential,'' ''predict,'' ''project,'' ''should,'' ''will,'' ''would'' and similar expressions. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements involve risks, uncertainties and other factors that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Investors are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. Dyadic expressly disclaims any intent or obligation to update or revise any forward-looking statements to reflect actual results, any changes in expectations or any change in events. Factors that could cause results to differ materially include, but are not limited to: (1) general economic, political and market conditions; (2) our ability to generate the required productivity, stability, purity, performance, cost, safety and other data necessary to carry out and implement our biopharmaceutical research and business plans and strategic initiatives; (3) our ability to retain and attract employees, consultants, directors and advisors; (4) our ability to implement and successfully carry out Dyadic's and third parties research and development efforts; (5) our ability to obtain new license and research agreements; (6) our ability to maintain our existing access to, and/or expand access to third party contract research organizations in order to carry out our research projects for ourselves and third parties; (7) competitive pressures and reliance on key customers and collaborators; (8) the pharmaceutical and biotech industry, governmental regulatory and other agencies' willingness to adopt, utilize and approve the use of the C1 gene expression platform; and (9) other factors discussed in Dyadic's publicly available filings, including information set forth under the caption ''Risk Factors'' in our December 31, 2017 Annual Report filed with the OTC Markets on March 27, 2018, and our March 31, 2018 Quarterly Report filed with the OTC Markets on May 10, 2018. New risks and uncertainties arise from time to time, and it is impossible for us to predict these events or how they may affect us.

Contacts:

Markku Saloheimo, Senior Principal Scientist
Tel. +358 405760892, markku.saloheimo@vtt.fi

Chris Landowski, Research Team Leader
Tel. +358 404820856, christopher.landowski@vtt.fi

Ronen Tchelet, VP, Research and Business Development
Tel. +36 30 864 6060, rtchelet@dyadic.com

SOURCE: Dyadic International, Inc.